StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$162.86−3.06 (-1.84%)

Close on Nov 18, 2026Market cap $16.55BP/E 23.9Yield –

Neurocrine Biosciences market cap

Market capitalization is the share price multiplied by the number of shares outstanding.

Neurocrine Biosciences's market cap was $17.72B on Nov 11, 2026, against $15.17B a year earlier. Over the last 5 years it ranged from $7.49B to $17.72B, with a median of $12.44B.

Market Cap at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$17.72B+25.3%
2025Dec 31, 2025$14.14B+2.4%
2024Dec 31, 2024$13.81B+6.8%
2023Dec 29, 2023$12.94B+12.7%
2022Dec 30, 2022$11.48B+42.2%
2021Dec 31, 2021$8.07B-9.8%
2020Dec 31, 2020$8.95B-9.6%
2019Dec 31, 2019$9.90B+52.9%
2018Dec 31, 2018$6.47B-5.7%
2017Dec 29, 2017$6.86B+104.2%
2016Dec 30, 2016$3.36B-30.8%
2015Dec 31, 2015$4.86B+186.2%
2014Dec 31, 2014$1.70B+169.9%
2013Dec 31, 2013$628.99M+26.7%
2012Dec 31, 2012$496.53M+5.7%
2011Dec 30, 2011$469.66M+57.1%
2010Dec 31, 2010$299.01M–

More Neurocrine Biosciences figures

See a number that looks wrong?